

GILEAD SCIENCES INC
Form 8-K
May 14, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 13, 2008

Gilead Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-19731

94-3047598

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

333 Lakeside Drive, Foster City, California

94404

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

650-574-3000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On May 13, 2008, James M. Denny, the lead independent director of the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into a new stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). Paul Berg, Ph.D., a member of the Company's Board of Directors, John C. Martin, PhD, Chairman, Board of Directors and Chief Executive Officer, John F. Milligan, PhD, President and Chief Operating Officer, Kevin Young, Executive Vice President, Commercial Operations, Gregg H. Alton, Senior Vice President and General Counsel, and Kristen M. Metzger, Senior Vice President, Human Resources, previously established stock trading plans under Rule 10b5-1, and certain other officers and directors of the Company may do so in the future. A copy of the press release is filed as Exhibit 99.1 to this report.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number Description

99.1 Press Release, issued by Gilead Sciences, Inc. on May 13, 2008

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Gilead Sciences, Inc.

May 14, 2008

By: *John F. Milligan, Ph.D.*

Name: John F. Milligan, Ph.D.

Title: President and Chief Operating Officer

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

Top of the Form

Exhibit Index

| Exhibit No. | Description |
|--------------------|--|
| 99.1 | Press Release, issued by Gilead Sciences, Inc. on May 13, 2008 |